Bio-Rad Laboratories, Inc.

Fundamentals6.0
Price Action5.0
News Sentiment4.0
AI Rating
5.0

Key Drivers

  • Liquidity Strength
  • Earnings Deterioration
  • Manageable Leverage

AI
AI Summary

5.0

BIO is no longer just a “cheap, high-quality” name—the key question is whether its strong balance sheet can offset the latest quarter's sharp earnings/EBITDA deterioration from weak academic demand, with upside only if profitability normalizes and the stock reclaims $300-$318 while holding $270 support.

EarningsRisk
BalanceSheet‍
ValuationSupport

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Liquidity Strength
  • Earnings Deterioration
  • Manageable Leverage

BIO remains financially sturdy with strong liquidity, manageable leverage, and positive free cash flow, but the latest quarter's steep drop to a large loss and negative EBITDA raises near-term earnings risk.

BalanceSheet
EarningsRisk

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term rebound
  • Overhead resistance
  • Volatile recovery

BIO's trend has softened over the last month, but the sharp rebound from $270.32 to $300.79 suggests a short-term recovery is forming as it tests resistance near $298-$300.

Rebound
Watch
Support Level: $270-$282
Resistance Level: $298-$300

Sharp rebound from $270.32 to $300.79 after the selloff suggests aggressive buying

Sentiment & News

4.0

Key News Insights:

  • Conference partnering
  • AI-driven workflows
  • BIO valuation gains

BIO 2026 dominated biotech headlines as companies used the convention to push AI-driven R&D, manufacturing, and partnership plans, while Bio-Rad (BIO) drew stock gains on valuation and balance-sheet strength.

BIO
Biotech

The mix of deal-making visibility and favorable stock reaction should keep BIO in focus, though regulatory-process concerns remain a modest overhang